Evidence map›Paper›PMID 38645965›Full record

ArticleTurkish journal of ophthalmology2024

Vasoproliferative Tumor Secondary to Sarcoidosis-Associated Intermediate Uveitis.

Sara Abdel Jalil, Tareq Jaouni, Radgonde Amer

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Turkish journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sara Abdel JalilHadassah Medical Center, Department of Ophthalmology, Jerusalem, Israel.ORCID 0009-0009-5150-3816
Tareq JaouniHadassah Medical Center, Department of Ophthalmology, Jerusalem, Israel.ORCID 0000-0001-5788-5952
Radgonde AmerHadassah Medical Center, Department of Ophthalmology, Jerusalem, Israel.ORCID 0000-0002-5730-4254
Hadassah Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the visual and clinical outcomes of a middle-aged woman who presented with exudative retinal detachment (ERD) secondary to a vasoproliferative tumor (VPT) in an eye with sarcoidosis-associated intermediate uveitis. A 55-year-old woman previously diagnosed with sarcoidosis presented with decreased vision in the left eye (LE). Visual acuity in the LE was counting fingers. She had active vitritis, and a peripheral retinal vascular mass was noted in the superotemporal periphery. The mass was associated with ERD involving the posterior pole. The patient was managed with systemic and intravitreal steroids, and cyclosporine was subsequently added as a steroid-sparing agent. Because of recurrence of ERD, the patient underwent pars plana vitrectomy, and cryotherapy and laser photocoagulation were applied to the VPT. Two months postoperatively, visual acuity in the LE improved to 6/10. There was marked regression of the VPT and total resolution of the ERD. In conclusion, we report a favorable visual and clinical outcome in a patient with VPT-associated ERD who responded to a combination of medical therapy and surgical intervention. VPT may lead to different remote complications, so timely diagnosis of these tumors and proper management of their complications is warranted.

Indexed as

Fluorescein AngiographyRetinal NeoplasmsSarcoidosisUveitis, IntermediateVisual AcuityFemaleFundus OculiGlucocorticoidsHumansMiddle AgedRetinal DetachmentTomography, Optical CoherenceVitrectomyGlucocorticoidsintermediate uveitispars planitissarcoidosisVasoproliferative tumor

Identifiers

PMID38645965
PMCPMC11034545
OpenAlexW4394965004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.